{'fraction_non_alphanumeric': 0.04748603351955307, 'fraction_numerical': 0.018156424581005588, 'mean_word_length': 5.128205128205129, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Phase I trial of pemetrexed (P) plus docetaxel (D) in advanced malignancies

13517 Background: P and D are active in patients (pts) with advanced malignancies. This trial sought to assess the maximum tolerated dose, dose-limiting toxicities (DLTs), tumor response, and the recommended Phase II dose of a P+D combination planned for pts with advanced cancer. Methods: Pts were enrolled with noncurable cancers, ≤1 prior regimen of chemotherapy for metastatic disease, no prior RT to ≥25% of bone marrow 7 days or febrile neutropenia, G4 or G3 (with bleeding) thrombocytopenia, and ≥G3 nonhematologic toxicities, except nausea, vomiting or elevated G3 ALT/AST. Response for measurable disease was assessed by RECIST...